<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article109</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ATTR-ACT" style="display:block; margin-bottom:10px;">ATTR-ACT Original</a></li>
<h2><strong>ATTR-ACT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Tafamidis in Transthyretin Amyloid Cardiomyopathy".The New England Journal of Medicine. 2019. 379(11):1007-1016.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with transthyretin amyloid cardiomyopathy, does treatment with tafamidis reduce all-cause mortality and cardiovascular-related hospitalizations?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with transthyretin amyloid cardiomyopathy, treatment with tafamidis significantly reduced all-cause mortality and cardiovascular-related hospitalizations, as well as the decline in functional capacity and quality of life, compared with placebo.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Transthyretin amyloid cardiomyopathy is characterized by the accumulation of amyloid fibrils composed of transthyretin protein in the heart, leading to cardiomyopathy and heart failure. Tafamidis is a benzoxazole derivative that binds to transthyretin, inhibiting its dissociation into monomers and subsequent amyloidogenesis.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the last update, no specific guidelines for the use of tafamidis in transthyretin amyloid cardiomyopathy were available.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, international, double-blind, placebo-controlled, phase 3 trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
441 patients with transthyretin amyloid cardiomyopathy.<br/>
<br/>
Inclusion Criteria<br/>
- Between 18 and 90 years of age<br/>
- Transthyretin amyloid cardiomyopathy confirmed by biopsy or scintigraphy<br/>
- Cardiac involvement confirmed by echocardiography, history of heart failure, NT-proBNP level above 600 pg/ml, and a 6-minute walk-test distance over 100 m<br/>
<br/>
Exclusion Criteria<br/>
- Heart failure not due to transthyretin amyloid cardiomyopathy<br/>
- NYHA class IV heart failure<br/>
- Light-chain amyloidosis<br/>
- History of organ transplantation<br/>
- Implanted cardiac device<br/>
- Previous tafamidis treatment<br/>
- Estimated glomerular filtration rate lower than 25 ml/min/1.73m²<br/>
- Liver transaminase levels exceeding two times the upper limit of normal<br/>
<br/>
Baseline Characteristics<br/>
- Median age: 75 years<br/>
- Mostly male patients<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- 80 mg of tafamidis (n=264)<br/>
- 20 mg of tafamidis (n=264)<br/>
- Placebo (n=177)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- Patients who received tafamidis had lower all-cause mortality and rate of cardiovascular-related hospitalizations than the placebo group (P&lt;0.001), with a win ratio of 1.695.<br/>
<br/>
Secondary Outcomes<br/>
- Improvement in the distance walked during the 6-minute walk test and KCCQ-OS scores, indicating reduced decline in functional capacity and quality of life, respectively.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Sponsored by Pfizer.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Further information can be found in the full text of the original article.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
